Dr. Hassan I. Tahsildar
Claim this profileBellin Memorial Hospital
Studies Lung Cancer
Studies Colorectal Cancer
22 reported clinical trials
53 drugs studied
Area of expertise
1Lung Cancer
Stage II
Stage I
Stage III
2Colorectal Cancer
Stage IV
dMMR negative
MSI-H negative
Affiliated Hospitals
Clinical Trials Hassan I. Tahsildar is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
More about Hassan I. Tahsildar
Clinical Trial Related6 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Hassan I. Tahsildar has experience with
- Atezolizumab
- Fluorouracil
- Nivolumab
- Ipilimumab
- Cisplatin
- Radiation Therapy
Breakdown of trials Hassan I. Tahsildar has run
Lung Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Hassan I. Tahsildar specialize in?
Hassan I. Tahsildar focuses on Lung Cancer and Colorectal Cancer. In particular, much of their work with Lung Cancer has involved Stage II patients, or patients who are Stage I.
Is Hassan I. Tahsildar currently recruiting for clinical trials?
Yes, Hassan I. Tahsildar is currently recruiting for 7 clinical trials in Green Bay Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Hassan I. Tahsildar has studied deeply?
Yes, Hassan I. Tahsildar has studied treatments such as Atezolizumab, Fluorouracil, Nivolumab.
What is the best way to schedule an appointment with Hassan I. Tahsildar?
Apply for one of the trials that Hassan I. Tahsildar is conducting.
What is the office address of Hassan I. Tahsildar?
The office of Hassan I. Tahsildar is located at: Bellin Memorial Hospital, Green Bay, Wisconsin 54301 United States. This is the address for their practice at the Bellin Memorial Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.